Triple monoamine reuptake inhibitor with strong appetite-suppressant effects.
Typical dose range: 0.25–1 mg
Frequency: Daily
Route: Oral
Half-life: ~9 days
Evidence level: Phase 3
Originally developed for Parkinson's, repurposed for obesity. Powerful weight loss but stimulant-class side effects (BP, HR, sleep).